Oncomed Pharmaceuticals Insider Austin Gurney Sells 4,000 Shares (OMED)
Oncomed Pharmaceuticals (NASDAQ:OMED) Insider Austin Gurney sold 4,000 shares of the company’s stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $24.99, for a total transaction of $99,960.00. Following the transaction, the insider now directly owns 105,532 shares of the company’s stock, valued at approximately $2,637,245. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on OMED. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. Separately, analysts at Zacks upgraded shares of Oncomed Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 13th. They now have a $23.10 price target on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Oncomed Pharmaceuticals from $50.00 to $48.00 in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Oncomed Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $37.78.
Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded up 3.47% during mid-day trading on Wednesday, hitting $25.95. 226,379 shares of the company’s stock traded hands. Oncomed Pharmaceuticals has a one year low of $12.07 and a one year high of $42.34. The stock’s 50-day moving average is $23.77 and its 200-day moving average is $29.12. The company’s market cap is $767.0 million.
Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.34. On average, analysts predict that Oncomed Pharmaceuticals will post $-0.76 earnings per share for the current fiscal year.
OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.